Video Experimental Relacionado
Updated: Jul 13, 2026
08:18
Methodology for Studying Interactions of Vitamin A Membrane Receptors and Opsin Protein with their Ligands in Generating the Retinylidene Protein
Published on: October 4, 2024
Diseño basado en la estructura de agonistas selectivos para un mutante asociado al raquitismo del receptor de
Steve L Swann1, Joel Bergh, Mary C Farach-Carson
1Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, USA.
Journal of the American Chemical Society
|November 15, 2002
Resumen
Los nuevos análogos no esteroideos del receptor de vitamina D (VDR) tratan eficazmente una mutación del VDR que causa raquitismo humano resistente a la vitamina D (hVDRR). Estos compuestos muestran una alta potencia y selectividad para el VDR nuclear, ofreciendo una estrategia terapéutica prometedora.
Área de la Ciencia:
- Endocrinología Endocrinología.
- Biología Molecular Biología Molecular
- Biología Estructural Biología estructural.
Sus antecedentes:
- Los receptores de hormonas nucleares y esteroides, incluido el receptor de vitamina D (VDR), regulan la transcripción génica para el desarrollo y la homeostasis.
- Las mutaciones en VDR están relacionadas con el raquitismo humano resistente a la vitamina D (hVDRR), caracterizado por un alto nivel sérico de 1,25 (((OH) ((2) D ((3)) y un grave subdesarrollo óseo.
- Los mutantes VDR asociados al hVDRR a menudo afectan la unión y la transactivación de los ligandos, particularmente la mutación Arg274 --> Leu que reduce la respuesta hormonal más de 1000 veces.
Objetivo del estudio:
- Diseñar y sintetizar nuevos análogos VDR no esteroideos dirigidos al mutante Arg274 -> Leu hVDRR-asociado.
- Evaluar la eficacia y potencia de estos análogos para complementar la función defectuosa del VDR.
- Evaluar la selectividad de los análogos diseñados para el VDR nuclear sobre las vías VDR asociadas a la membrana.
Principales métodos:
- El diseño molecular asistido por computadora se empleó para crear una biblioteca enfocada de análogos no esteroideos basados en el agonista VDR LG190155.5.
- Los análogos fueron diseñados para complementar específicamente los déficits estructurales y funcionales causados por la mutación Arg274 --> Leu en el VDR.
- La actividad de los análogos diseñados y los compuestos de control se evaluó en el contexto del mutante VDR. asociado al hVDRR.
Principales resultados:
- La mitad de los análogos no esteroideos diseñados demostraron una actividad sustancial en el mutante Arg274 --> Leu hVDRR.
- Los compuestos de control estructuralmente similares no mostraron actividad significativa, destacando la especificidad de los análogos diseñados.
- Los siete análogos más potentes fueron de 16 a 526 veces más efectivos que 1,25 ((OH) ((2) D ((3) en el receptor mutante, con valores de EC ((50) que oscilaron entre 3,3 y 121 nM.
- Estos análogos activaron selectivamente el VDR nuclear sin estimular la afluencia de calcio celular, lo que indica que no se ha activado el VDR asociado a la membrana.
Conclusiones:
- Los nuevos análogos VDR no esteroideos pueden atacar y activar eficazmente los mutantes VDR asociados con hVDRR.
- Los análogos diseñados exhiben una potencia y selectividad significativamente más altas en comparación con la hormona natural 1,25 (OH) (D) en el contexto de la mutación específica.
- Estos hallazgos presentan una vía terapéutica prometedora para la hVDRR mediante el desarrollo de moduladores selectivos de VDR que eluden la función de unión de ligando defectuosa.
Más Videos Relacionados
10:01Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Videos de Conceptos Relacionados
01:25Drug-Receptor Bonds
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...